{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:51:58Z","timestamp":1781779918856,"version":"3.54.5"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>While biologics have been used for the patients with psoriatic arthritis, there remains to be unknown concerning long-term retention rates. This study aims to present real-world data about long-term retention rates of biologics for the patients with psoriatic arthritis, and to undertake an analysis of the contributing factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We examined retention rates and the reasons for discontinuation for biologics (adalimumab, certolizumab pegol, secukinumab, and ixekizumab) in 146 prescriptions (of which, 109 prescriptions were as naive) at our hospital since March 2010.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Throughout the entire course of the study, the 10-year retention rates were approximately 70% for adalimumab, 50% for ixekizumab, and 40% for secukinumab. When evaluating retention rates in the biologic-na\u00efve subgroups, the 10-year retention rates were all approximately 70%. Regarding certolizumab pegol, the 3-year retention rate was approximately 75%. For adalimumab, a higher degree of arthritis at the initiation of treatment was found to correlate with an increased likelihood of secondary inefficacy. The main reason for discontinuation was secondary inefficacy, except for ixekizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Each biologic exhibited a favourable long-term retention rate. The main reason for discontinuation was secondary inefficacy. Regarding adalimumab, secondary inefficacy was linked to the extent of arthritis upon treatment initiation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/road111","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T07:44:20Z","timestamp":1701848660000},"page":"1013-1018","source":"Crossref","is-referenced-by-count":10,"title":["Long-term retention rates of\u00a0anti-tumour necrosis factor and\u00a0anti-interleukin-17 antibodies for\u00a0patients with psoriatic arthritis"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2708-4377","authenticated-orcid":false,"given":"Kenji","family":"Takami","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyoshi","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachina","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Akaji","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Hiroumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hachiro","family":"Konaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Higashiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Life Hospital , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"2024101507121525400_R1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3899\/jrheum.141598","article-title":"Prevalence and\u00a0clinical characteristics of\u00a0psoriatic arthritis in\u00a0Japan","volume":"42","author":"Ohara","year":"2015","journal-title":"J Rheumatol"},{"key":"2024101507121525400_R2","first-page":"1041","article-title":"Comparison of\u00a0radiological severity in\u00a0psoriatic arthritis and\u00a0rheumatoid arthritis","volume":"28","author":"Rahman","year":"2001","journal-title":"J Rheumatol"},{"key":"2024101507121525400_R3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for\u00a0the management of\u00a0psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024101507121525400_R4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of\u00a0psoriatic arthritis: a systematic literature research for\u00a0the 2019 update of\u00a0the EULAR recommendations for\u00a0the management of\u00a0psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024101507121525400_R5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for\u00a0Research and\u00a0Assessment of\u00a0Psoriasis and\u00a0Psoriatic Arthritis (GRAPPA): updated treatment recommendations for\u00a0psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024101507121525400_R6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/acr.23090","article-title":"Eight-year retention rate of\u00a0first-line tumor necrosis factor inhibitors in\u00a0spondyloarthritis: a multicenter retrospective analysis","volume":"69","author":"Favalli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024101507121525400_R7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for\u00a0treatment of\u00a0active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2024101507121525400_R8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and\u00a0safety of\u00a0ixekizumab versus adalimumab in\u00a0patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024101507121525400_R9","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.2004.028530","article-title":"Why results of\u00a0clinical trials and\u00a0observational studies of\u00a0antitumour necrosis factor (anti-TNF) therapy differ: methodological and\u00a0interpretive issues","volume":"63","author":"Wolfe","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2024101507121525400_R10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on\u00a0TNF inhibitors in\u00a0patients with rheumatoid arthritis comparison of\u00a0adalimumab, etanercept and\u00a0infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024101507121525400_R11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of\u00a07 biologics and\u00a0tofacitinib in\u00a0biologics-na\u00efve and\u00a0biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024101507121525400_R12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030444","article-title":"Retention rate of\u00a0secukinumab in\u00a0psoriatic arthritis: real-world data results from a Spanish multicenter cohort","volume":"101","author":"Valero-Exp\u00f3sito","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2024101507121525400_R13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020467","article-title":"Treatment retention and\u00a0safety of\u00a0ixekizumab in\u00a0psoriatic arthritis: a real life single-center experience","volume":"12","author":"Bra\u00f1a","year":"2023","journal-title":"J Clin Med"},{"key":"2024101507121525400_R14","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","article-title":"Predictive factors for\u00a0switching in\u00a0patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study","volume":"40","author":"Lorenzin","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2024101507121525400_R15","article-title":"Real-life retention rates and\u00a0reasons for\u00a0switching of\u00a0biological DMARDs in\u00a0rheumatoid arthritis, psoriatic arthritis, and\u00a0ankylosing spondylitis","volume":"8","author":"Bhushan","year":"2021","journal-title":"Front Med Lausanne"},{"key":"2024101507121525400_R16","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of\u00a0biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2024101507121525400_R17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1080\/09546634.2020.1854428","article-title":"Drug survival of\u00a0secukinumab, ustekinumab, and\u00a0certolizumab pegol in\u00a0psoriasis: a 2-year, monocentric, retrospective study","volume":"33","author":"Chatzimichail","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2024101507121525400_R18","article-title":"Persistence of\u00a0biologic treatments in\u00a0psoriatic arthritis: a population-based study in\u00a0Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2024101507121525400_R19","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2023.1544","article-title":"Retention rate of\u00a0tumor necrosis factor inhibitors, anti-interleukin 17, and\u00a0anti-interleukin 12\/23 drugs in\u00a0a single-center cohort of\u00a0psoriatic arthritis patients","volume":"75","author":"Ferrito","year":"2023","journal-title":"Reumatismo"},{"key":"2024101507121525400_R20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and\u00a0tolerability of\u00a0anti-tumour necrosis factor therapy in\u00a0psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024101507121525400_R21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002802","article-title":"Factors associated with the retention of\u00a0secukinumab in\u00a0patients with axial spondyloarthritis in\u00a0real-world practice: results from a retrospective study (FORSYA)","volume":"9","author":"Dougados","year":"2023","journal-title":"RMD Open"},{"key":"2024101507121525400_R22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of\u00a0DMARDs in\u00a0reducing the immunogenicity of\u00a0TNF inhibitors in\u00a0chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2024101507121525400_R23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of\u00a0TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front Immunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/road111\/54532661\/road111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/1013\/59755362\/road111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/5\/1013\/59755362\/road111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T07:15:22Z","timestamp":1728976522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/5\/1013\/7475918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,7]]},"published-print":{"date-parts":[[2024,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/road111","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2023,12,7]]}}}